# Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers

> **NCT04808622** · PHASE1 · COMPLETED · sponsor: **Diffusion Pharmaceuticals Inc** · enrollment: 30 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Trans-Sodium Crocetinate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04808622
- **Lead sponsor:** Diffusion Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-17
- **Primary completion:** 2021-03-21
- **Final completion:** 2021-03-25
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04808622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04808622, "Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04808622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*